Classification and visualization of longitudinal patterns of medication dose: An application to interferon‐beta‐1a and amitriptyline in patients with multiple sclerosis

Describing patterns of use, including changes in dose and interruptions is challenging. Group‐based trajectory modelling (GBTM) can be used to identify individuals with similar dose patterns. We provide an intuitive graphical representation of dose patterns in groups identified using GBTM. We illustrate our approach using two drugs with different combinations of available dosages.

[1]  Stephen G. Henry,et al.  Longitudinal Dose Trajectory Among Patients Tapering Long-Term Opioids. , 2021, Pain medicine.

[2]  R. Fillingim,et al.  Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study , 2019, PLoS medicine.

[3]  J. Singer,et al.  Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: Growth mixture modeling using data from prospective cohort studies. , 2019, Addiction.

[4]  B. Peterlin,et al.  Pharmacogenomics of Multiple Sclerosis: A Systematic Review , 2019, Front. Neurol..

[5]  R. Xu,et al.  Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose , 2018, Pharmacoepidemiology and drug safety.

[6]  C. Chambers,et al.  Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period , 2018, Archives of Women's Mental Health.

[7]  G. Pardo,et al.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations , 2017, Journal of Neurology.

[8]  C. François,et al.  Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis , 2017, BMC Psychiatry.

[9]  Sarah Depaoli,et al.  The GRoLTS-Checklist: Guidelines for Reporting on Latent Trajectory Studies , 2016 .

[10]  K. Myhr,et al.  Disease-modifying treatments for multiple sclerosis – a review of approved medications , 2015, European journal of neurology.

[11]  M. Benedetti,et al.  Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? , 2015, World journal of clinical cases.

[12]  Anthony J. Culyer.  Institut National d’excellence en Santé et en Services Sociaux , 2014 .

[13]  M. Sylvestre,et al.  Does pregnancy alter the long-term course of multiple sclerosis? , 2014, Annals of epidemiology.

[14]  D. Wingerchuk,et al.  Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. , 2014, Mayo Clinic proceedings.

[15]  Jos Twisk,et al.  Classifying developmental trajectories over time should be done with great caution: a comparison between methods. , 2012, Journal of clinical epidemiology.

[16]  Jeroen K. Vermunt,et al.  Latent class modeling with covariates : Two improved three-step approaches 1 , 2012 .

[17]  A. Matcho,et al.  Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States , 2010, BMC palliative care.

[18]  G. Gronseth,et al.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis , 2010, Neurology.

[19]  C. Anderson‐Cook,et al.  Group-Based Modeling of Development , 2006 .

[20]  F. Munschauer,et al.  Neutralising antibodies to interferon beta during the treatment of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[21]  D. Konradis.  Multiple Sclerosis Society of Canada. , 1971, Canadian journal of public health = Revue canadienne de sante publique.